Kaken Pharmaceutical Co Ltd 2021 Integrated Report
The report sets out KAKEN's FY2020 value-creation model and five priority issues covering medical solutions, pharmaceutical responsibilities, governance, the environment and fulfilling workplaces. It highlights approval and the November 2020 launch of Ecclock Gel 5%, Japan's first topical treatment for primary axillary hyperhidrosis. Consolidated net sales were ¥74,979 million, while CO2 emissions were 20,605 t-CO2.
Company: Kaken Pharmaceutical Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2021
Type: Integrated Report
Pages: 37
Back to company
Kaken Pharmaceutical Co Ltd
Corporate Report
The report sets out KAKEN's FY2020 value-creation model and five priority issues covering medical solutions, pharmaceutical responsibilities, governance, the environment and fulfilling workplaces. It highlights approval and the November 2020 launch of Ecclock Gel 5%, Japan's first topical treatment for primary axillary hyperhidrosis. Consolidated net sales were ¥74,979 million, while CO2 emissions were 20,605 t-CO2.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Apr 1, 2020 - Mar 31, 2021
Fiscal Year
2020
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Water Consumption
Total Waste
Women on Board
Employees